{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:35:47Z","timestamp":1789529747823,"version":"build-2803163510"},"reference-count":23,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Cannabis Cannabinoids"],"abstract":"<b><i>Introduction:<\/i><\/b> Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. In vitro studies suggest CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1). The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH). <b><i>Methods:<\/i><\/b> In a randomized, placebo-controlled, crossover study, 12 subjects ingested 750 mg of CBD solution, or alternatively, a placebo solution twice daily for a 3-day run-in period followed by an additional CBD dose (or placebo) and a single 10 mg dose of MPH and completed serial blood sampling for pharmacokinetic analysis. MPH and CBD concentrations were measured by liquid chromatography with tandem mass spectrometry. <b><i>Results:<\/i><\/b> The C<sub>max<\/sub> (mean \u00b1 CV) for the CBD group and placebo group was 13.5 \u00b1 43.7% ng\/mL and 12.2 \u00b1 36.4% ng\/mL, respectively. AUC<sub>inf<\/sub> (ng\/mL*h) for the CBD group and placebo group was 70.7 \u00b1 32.5% and 63.6 \u00b1 25.4%, respectively. The CBD AUC<sub>0-8h<\/sub> (mean \u00b1 CV) was 1,542.2 \u00b1 32% ng\/mL*h, and C<sub>max<\/sub> was 389.2 \u00b1 39% ng\/mL. When compared to MPH only, the geometric mean ratio (CBD\/control, 90% CI) for AUC<sub>inf<\/sub> and C<sub>max<\/sub> with CBD co-administration was 1.09 (0.89, 1.32) and 1.08 (0.85, 1.37), respectively. <b><i>Discussion\/Conclusion:<\/i><\/b> Although the upper bound of bioequivalence was not met, the mean estimates of AUC and C<sub>max<\/sub> ratios were generally small and unlikely to be of clinical significance. <\/jats:p>","DOI":"10.1159\/000527189","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T22:00:38Z","timestamp":1667599238000},"page":"199-206","source":"Crossref","is-referenced-by-count":12,"title":["The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects"],"prefix":"10.1159","volume":"5","author":[{"given":"John S.","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"De Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Melchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1841-1401","authenticated-orcid":false,"given":"Reginald F.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon O.","family":"Klee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2189","authenticated-orcid":false,"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"ref1"},{"key":"ref2"},{"key":"ref3"},{"key":"ref4"},{"key":"ref5"},{"key":"ref6"},{"key":"ref7"},{"key":"ref8"},{"key":"ref9"},{"key":"ref10"},{"key":"ref11"},{"key":"ref12"},{"key":"ref13"},{"key":"ref14"},{"key":"ref15"},{"key":"ref16"},{"key":"ref17"},{"key":"ref18"},{"key":"ref19"},{"key":"ref20"},{"key":"ref21"},{"key":"ref22"},{"key":"ref23"}],"container-title":["Medical Cannabis and Cannabinoids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/527189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/527189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:23:48Z","timestamp":1745421828000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000527189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,2]]}},"URL":"https:\/\/doi.org\/10.1159\/000527189","archive":["Portico"],"relation":{},"ISSN":["2504-3889"],"issn-type":[{"value":"2504-3889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]}}}